What is the recommended management for type 2 diabetes in patients undergoing dialysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Type 2 Diabetes in Patients Undergoing Dialysis

For patients with type 2 diabetes undergoing dialysis, insulin therapy is the preferred treatment approach due to decreased renal clearance of insulin and contraindications for many oral agents.1

Glycemic Monitoring and Targets

  • HbA1c measurements have low reliability in dialysis patients due to anemia, decreased red blood cell lifespan, and uremic toxins 2
  • Continuous glucose monitoring (CGM) or frequent self-monitoring of blood glucose (SMBG) is recommended as the preferred method for glycemic assessment in dialysis patients 2
  • A glucose management indicator (GMI) derived from CGM data can be used when HbA1c is not concordant with directly measured blood glucose levels 2
  • Glycemic targets should be less stringent for dialysis patients, with HbA1c targets of 7-8% being appropriate to reduce hypoglycemia risk 2

Medication Management

Insulin Therapy

  • Standard starting insulin dose should be reduced to 0.5 units/kg/day due to decreased renal clearance 1
  • Divide total daily insulin dose as 50% basal and 50% bolus (rapid-acting) insulin 1
  • Analog insulins are preferred over human insulin as they are associated with:
    • Lower all-cause mortality (22.0% vs 31.4%) 3
    • Reduced major adverse cardiovascular events (26.8% vs 35.9%) 3
    • Fewer hospitalizations (58.2% vs 75.0%) 3
    • Similar rates of hypoglycemia compared to human insulin 3

Oral Antidiabetic Agents

  • Metformin is contraindicated in patients on dialysis 2
  • SGLT2 inhibitors should be discontinued in patients on dialysis 2
  • DPP-4 inhibitors (particularly sitagliptin 25mg daily) can be used safely in dialysis patients 4
  • GLP-1 receptor agonists may be considered in select patients on dialysis, particularly for those with atherosclerotic cardiovascular disease 2

Nutritional Management

  • Patients on hemodialysis should consume 1.0-1.2 g protein/kg/day 2
  • Patients on peritoneal dialysis should consume slightly higher protein intake (1.2-1.3 g/kg/day) due to protein losses in dialysate 2
  • Sodium intake should be limited to <2 g per day 2, 5
  • Diet should be high in vegetables, fruits, whole grains, fiber, legumes, plant-based proteins, unsaturated fats, and nuts; and lower in processed meats, refined carbohydrates, and sweetened beverages 2

Physical Activity

  • Patients should undertake moderate-intensity physical activity for at least 150 minutes per week, adjusted to their cardiovascular and physical tolerance 2
  • Patients should be advised to avoid sedentary behavior 2
  • For patients at higher risk of falls, consider recommending low to moderate intensity exercises 2

Hypoglycemia Prevention and Management

  • Hypoglycemia risk is increased in dialysis patients due to decreased insulin clearance, impaired gluconeogenesis, and malnutrition 2, 1
  • Immediate treatment for hypoglycemia should include 15-20g of glucose for conscious patients 2
  • For patients with cognitive impairment, administer 20-40 ml of 50% glucose solution intravenously or glucagon 0.5-1.0 mg intramuscularly 2
  • Monitor blood glucose every 15 minutes after treatment until normalized 2

Special Considerations

  • Peritoneal dialysis patients may experience glucose absorption from dialysate, making glycemic control more challenging 6
  • Automated insulin delivery (AID) systems have shown promise in improving glycemic control in dialysis patients, with studies showing significantly higher time in range (69.0% vs 31.5%) compared to conventional insulin therapy 2
  • Continuous glucose monitoring can be affected by uremic toxins in dialysis patients, which may interfere with sensor accuracy 2

Multidisciplinary Approach

  • Involve registered dietitians, diabetes educators, and nephrologists in the care team 2
  • Consider cultural differences, food intolerances, resource variations, and comorbidities when developing treatment plans 2
  • Regular monitoring for cardiovascular complications is essential as dialysis patients with diabetes have high cardiovascular risk 2, 7

By following these guidelines, clinicians can optimize the management of type 2 diabetes in patients undergoing dialysis, with the goal of reducing complications and improving quality of life.

References

Guideline

Insulin Management for Type 2 Diabetes Patients with Severe Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2024

Research

Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013

Guideline

Comprehensive Management of Metabolic Abnormalities

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diabetes mellitus and dialysis.

Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.